Citigroup’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-8
| Closed | -$6 | – | 5845 |
|
|
2023
Q1 | $6 | Hold |
8
| – | – | ﹤0.01% | 5425 |
|
|
2022
Q4 | $7 | Sell |
8
-6,577
| -100% | -$19.1K | ﹤0.01% | 5727 |
|
|
2022
Q3 | $40K | Sell |
6,585
-488
| -7% | -$2.77K | ﹤0.01% | 4492 |
|
|
2022
Q2 | $29K | Buy |
+7,073
| New | +$24.9K | ﹤0.01% | 4808 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 6442 |
|
|
2021
Q2 | $0 | Sell |
1
-609
| -100% | -$3.28K | ﹤0.01% | 6503 |
|
|
2021
Q1 | $4K | Sell |
610
-1,160
| -66% | -$7.03K | ﹤0.01% | 5969 |
|
|
2020
Q4 | $8K | Buy |
1,770
+1,328
| +300% | +$5.72K | ﹤0.01% | 7022 |
|
|
2020
Q3 | $2K | Sell |
442
-804
| -65% | -$16.2K | ﹤0.01% | 7333 |
|
|
2020
Q2 | $36K | Sell |
1,246
-12
| -1% | -$278 | ﹤0.01% | 6223 |
|
|
2020
Q1 | $27K | Buy |
1,258
+370
| +42% | +$8.4K | ﹤0.01% | 6493 |
|
|
2019
Q4 | $18K | Buy |
+888
| New | +$12.6K | ﹤0.01% | 6987 |
|
Citigroup's STSA Position: Q2 2023 in Review
Citigroup sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 8 shares — an estimated $6 sold.
Citigroup first reported a position in STSA in Q4 2019 and held it in 11 quarters. The position peaked at $40K in Q3 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Citigroup reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citigroup sold 8 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $6.
- Citigroup first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
- Citigroup's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $40K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.